A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients

Transplant Proc. Nov-Dec 2001;33(7-8):3192-3. doi: 10.1016/s0041-1345(01)02357-0.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Acute Disease
  • Antibodies, Monoclonal / therapeutic use*
  • Antilymphocyte Serum / therapeutic use*
  • Basiliximab
  • Cytomegalovirus Infections / epidemiology
  • Graft Rejection / epidemiology
  • Graft Survival
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / methods
  • Pilot Projects
  • Postoperative Complications / classification
  • Postoperative Complications / epidemiology
  • Recombinant Fusion Proteins*

Substances

  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab